Your AI-Trained Oncology Knowledge Connection!
Julie R. Brahmer, MD, discusses advances made with immunotherapy in the lung cancer space, highlights challenges that still need to be addressed, and sheds light on ongoing research designed to determine treatment approaches beyond PD-1/PD-L1 and CTLA-4 inhibition
First- and second-generation TKIs confer a significant survival benefit for patients with chronic-phase chronic myeloid leukemia (CP-CML)—so much so, that treatment discontinuation has become a viable option for select patients.
Edward B. Garon, MD, discusses the landscape of EGFR-targeted therapy in non–small cell lung cancer.
Stereotactic body radiation therapy has been found to be a safe and effective option for patients with low- and intermediate-risk prostate cancer.
Jesus Berdeja, MD, discusses emerging standards of care in transplant-eligible and -ineligible patients with newly diagnosed multiple myeloma.
Jordan Gauthier, MD, MSc, discusses retrospective results of concurrent ibrutinib and JCAR014 and where chimeric antigen receptor T-cell research is headed for patients with chronic lymphocytic leukemia.
The FDA has approved a split-dosing regimen of daratumumab for patients with multiple myeloma, providing physicians the option to split the first infusion of the CD38-directed monoclonal antibody over 2 consecutive days or complete in a single session.
Victor A. Chow, MD, discusses the next steps in understanding how to treat patients with large B-cell lymphomas who progress after chimeric antigen receptor T-cell therapy.
Heather Wakelee, MD, shares insight on the current landscape of lung cancer and discussed how immunotherapy and targeted therapy can be improved for patients with non–small cell lung cancer.
The FDA has granted a priority review designation to a supplemental biologics license application for the combination of avelumab and axitinib as a treatment for patients with advanced renal cell carcinoma.
The RAINBOW and TAGS trials have demonstrated strong evidence to support the use of ramucirumab and TAS-102 in patients with advanced gastric or gastroesophageal cancer who have progressed on first-line therapy.
The European Commission has approved brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with CD30+ stage IV Hodgkin lymphoma.
Robert L. Talley, MD, discusses current and potential future standards of care in idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura.
The FDA has granted a priority review designation to a supplemental biologics license application for pembrolizumab (Keytruda) alone or in combination with platinum and 5-fluorouracil chemotherapy as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.
The European Commission has approved dasatinib in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Manish A. Shah, MD, discusses the results of the GAMMA-1 trial and challenges that remain for patients with gastric cancer.
Earlier diagnosis and more effective therapeutic options are enabling physicians to deliver better rates of disease control and improved quality of life to patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Byrne Lee, MD, discusses regional treatment strategies for patients with metastatic colorectal cancer.
The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for February 26, 2019, to discuss a new drug application for selinexor in combination with dexamethasone for the treatment of patients with penta-refractory multiple myeloma.
The FDA has added 3 months to the review period for a supplemental new drug application for ruxolitinib for the treatment of patients with acute graft-versus-host disease who have had an inadequate response to corticosteroids, making the new action date May 24, 2019.
Massimo Cristofanilli, MD, discusses the clinical utility of liquid biopsies—specifically focusing on circulating tumor cells and cell-free DNA—and highlights ongoing research in the space.
Marwan Fakih, MD, discusses recent trials in colorectal cancer and highlights other ongoing research in the field.
Sarah Holstein, MD, PhD, highlights the vast treatment paradigm of myeloma and shared some considerations for sequencing.
Erika P. Hamilton, MD, reflects on the latest data in HER2-positive breast cancer and additional therapies moving through the pipeline.
The relative risk of developing a solid subsequent malignant neoplasm remained elevated in survivors of childhood Hodgkin lymphoma, according to extended follow-up of more than 25 years from the Late Effects Study Group cohort.
Margetuximab in combination with chemotherapy improved progression-free survival compared with trastuzumab and chemotherapy in heavily pretreated patients with metastatic HER2-positive breast cancer.
The FDA has approved the nanobody caplacizumab-yhdp in combination with plasma exchange and immunosuppression for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura, making it the first FDA-approved therapy indicated for this patient population.
Geoffrey R. Oxnard, MD, discusses the use of cell-free DNA as a potential method of cancer detection and subsequent assessment of treatment response in patients with solid and hematologic malignancies.
Komal Jhaveri, MD, discusses the 3 major classes of drugs showing potential in the TNBC pipeline.
The FDA has granted a priority review designation to a new drug application for the investigational, small molecule, CSF1R receptor inhibitor pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor.
